Skip Navigation

European Heart Journal 1992 13(5):666-670;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by VAAGE-NILSEN, M.
Right arrow Articles by HANSEN, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VAAGE-NILSEN, M.
Right arrow Articles by HANSEN, J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Prevalence of transient myocardial ischaemia during the first year after a myocardial infarction. Effect of treatment with verapamil

M. VAAGE-NILSEN, V. RASMUSSEN, N. H. HOLLÄNDER* and J. FISCHER HANSEN

The Holter Laboratory of Hvidovre University Hospital, Department of Medicine II, Municipal Hospital Copenhagen Denmark
*Department of Internal Medicine, Roskilde County Hospital Denmark

Received 6 November 1990; revised 11 June 1991; .

Correspondence Merete Vaage-Nilsen MD, The County Hospital of Hillered, Helsevej 2, DK-3400 Hillerod, Denmark

Abstract

DAVIT-II is a double-blind, randomized, multicentre, placebo-controlled study of long-term treatment with verapamil 360 mg per day administered to patients who have suffered an acute myocardial infarction (AMI). In the present study, comprising a subset of DA VIT-II, 48 h continuous ECG recordings demonstrated transient ST segment deviation indicative of myocardial ischaemia after one week, prior to randomization, in 18% (10 of 57) of the patients. After one month, 24% (11 of 46) of the placebo and 8% (3 of 39) of the verapamil-treated patients (P=0.04) had myocardial ischaemia; after one year the figures were 26% (9 of 35) and 4% (1 of 27) (P=0.02), respectively. At 18 months the ‘major’ event rate in patients who had had ischaemia before randomization was 40% and 23.8% in patients without ischaemia (P=0.057). In the placebo group, 63% of 91 episodes of ST depression were recorded between 0600 h and 1800 h, and 62% of 26 episodes of ST elevation between 1800 h and0600 h(P<0–001). Nine episodes of ST depression and no episode of ST elevation were recorded in the verapamil-treated patients. In conclusion, 20–25% of post-AM I patients have transient ischaemia; verapamil prevents ischaemia, and a pronounced circadian variation of ST segment deviations can be demonstrated.

Key Words: Holter monitoring • verapamil • myocardial ischaemia • circadian variation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.